Literature DB >> 9510479

Adeno-associated virus vector containing the herpes simplex virus thymidine kinase gene causes complete regression of intracerebrally implanted human gliomas in mice, in conjunction with ganciclovir administration.

M Mizuno1, J Yoshida, P Colosi, G Kurtzman.   

Abstract

Adeno-associated virus (AAV) has attracted considerable interest as a potential vector for gene therapy because of its wide host range, high transduction efficiency, and lack of cytopathogenicity. In this experiment, we evaluated the efficacy of AAV vector containing the herpes simplex virus thymidine kinase (HSV-tk) gene on human gliomas transplanted into the brain of nude mice. Complete regression of the tumors was observed after multiple AAV-tk injections followed by intraperitoneal ganciclovir (GCV) administration, and the survival of mice treated with AAV-tk vector and GCV administration was markedly prolonged. These results suggest that AAV-tk vectors may be useful for gene therapy against malignant gliomas in humans.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9510479      PMCID: PMC5921591          DOI: 10.1111/j.1349-7006.1998.tb00482.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  13 in total

Review 1.  Brain tumors. Part 2.

Authors:  P M Black
Journal:  N Engl J Med       Date:  1991-05-30       Impact factor: 91.245

Review 2.  Adeno-associated viruses: an update.

Authors:  K I Berns; R A Bohenzky
Journal:  Adv Virus Res       Date:  1987       Impact factor: 9.937

3.  'Bystander killing' induces apoptosis and is inhibited by forskolin.

Authors:  Y Samejima; D Meruelo
Journal:  Gene Ther       Date:  1995-01       Impact factor: 5.250

4.  In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy.

Authors:  W L Bi; L M Parysek; R Warnick; P J Stambrook
Journal:  Hum Gene Ther       Date:  1993-12       Impact factor: 5.695

5.  Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy.

Authors:  F L Moolten
Journal:  Cancer Res       Date:  1986-10       Impact factor: 12.701

6.  Gene therapy against an experimental glioma using adeno-associated virus vectors.

Authors:  H Okada; K Miyamura; T Itoh; M Hagiwara; T Wakabayashi; M Mizuno; P Colosi; G Kurtzman; J Yoshida
Journal:  Gene Ther       Date:  1996-11       Impact factor: 5.250

7.  The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified.

Authors:  S M Freeman; C N Abboud; K A Whartenby; C H Packman; D S Koeplin; F L Moolten; G N Abraham
Journal:  Cancer Res       Date:  1993-11-01       Impact factor: 12.701

8.  Curative potential of herpes simplex virus thymidine kinase gene transfer in rats with 9L gliosarcoma.

Authors:  V Cool; B Pirotte; C Gérard; J L Dargent; N Baudson; M Levivier; S Goldman; J Hildebrand; J Brotchi; T Velu
Journal:  Hum Gene Ther       Date:  1996-03-20       Impact factor: 5.695

9.  Efficient gene transfer into nondividing cells by adeno-associated virus-based vectors.

Authors:  G Podsakoff; K K Wong; S Chatterjee
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

10.  In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors.

Authors:  K W Culver; Z Ram; S Wallbridge; H Ishii; E H Oldfield; R M Blaese
Journal:  Science       Date:  1992-06-12       Impact factor: 47.728

View more
  20 in total

Review 1.  Gene therapy for brain tumors.

Authors:  K Bansal; H H Engelhard
Journal:  Curr Oncol Rep       Date:  2000-09       Impact factor: 5.075

Review 2.  Adeno-associated virus vectors: potential applications for cancer gene therapy.

Authors:  Chengwen Li; Dawn E Bowles; Terry van Dyke; Richard Jude Samulski
Journal:  Cancer Gene Ther       Date:  2005-12       Impact factor: 5.987

3.  Viral nanoparticles as macromolecular devices for new therapeutic and pharmaceutical approaches.

Authors:  Simone Grasso; Luca Santi
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2010-07-06

4.  Comparative evaluation of preclinical in vivo models for the assessment of replicating retroviral vectors for the treatment of glioblastoma.

Authors:  Juraj Hlavaty; Gerrit Jandl; Melissa Liszt; Helga Petznek; Marielle König-Schuster; Jenny Sedlak; Monika Egerbacher; Jakob Weissenberger; Brian Salmons; Walter H Günzburg; Matthias Renner
Journal:  J Neurooncol       Date:  2010-07-11       Impact factor: 4.130

5.  Improved Adeno-associated Viral Gene Transfer to Murine Glioma.

Authors:  I Zolotukhin; D Luo; Os Gorbatyuk; Be Hoffman; Kh Warrington; Rw Herzog; Jk Harrison; O Cao
Journal:  J Genet Syndr Gene Ther       Date:  2013-04-29

Review 6.  Gene therapy and targeted toxins for glioma.

Authors:  Maria G Castro; Marianela Candolfi; Kurt Kroeger; Gwendalyn D King; James F Curtin; Kader Yagiz; Yohei Mineharu; Hikmat Assi; Mia Wibowo; A K M Ghulam Muhammad; David Foulad; Mariana Puntel; Pedro R Lowenstein
Journal:  Curr Gene Ther       Date:  2011-06       Impact factor: 4.391

Review 7.  Gene therapy and targeted toxins for glioma.

Authors:  Gwendalyn D King; James F Curtin; Marianela Candolfi; Kurt Kroeger; Pedro R Lowenstein; Maria G Castro
Journal:  Curr Gene Ther       Date:  2005-12       Impact factor: 4.391

8.  Directed evolution of adeno-associated virus for glioma cell transduction.

Authors:  Casey A Maguire; Davide Gianni; Dimphna H Meijer; Lev A Shaket; Hiroaki Wakimoto; Samuel D Rabkin; Guangping Gao; Miguel Sena-Esteves
Journal:  J Neurooncol       Date:  2009-07-19       Impact factor: 4.130

Review 9.  Adenoviral virotherapy for malignant brain tumors.

Authors:  Suvobroto Nandi; Maciej S Lesniak
Journal:  Expert Opin Biol Ther       Date:  2009-06       Impact factor: 4.388

Review 10.  Gene therapy as an adjuvant treatment for malignant gliomas: from bench to bedside.

Authors:  Isabelle M Germano; Emanuela Binello
Journal:  J Neurooncol       Date:  2009-05-09       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.